Beta-blockade today: the gap between evidence and practice
Open Access
- 1 June 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 8 (suppl_C) , C28-C34
Abstract
Current European Society of Cardiology guidelines for chronic heart failure (CHF) recommend the use of beta-blockers in all symptomatic patients with systolic dysfunction. Beta-blockers reduce CHF mortality by >30% and also reduce hospitalizations. Given at appropriate doses, they are generally well tolerated, even in the elderly. However, two large European surveys [IMPROVEMENT in primary care and Euro Heart Failure Survey (EURO-HF) in hospitalized patients] show that beta-blockers are used in only 34–37% of patients, with a wide variation between countries. The frequency of beta-blocker prescription in patients ≥75 years of age is <20%. A recent analysis of EURO-HF showed that, even among CHF patients who met the criteria for the landmark trials, without comorbidities or other risk factors, beta-blockers are used in <50% of cases. General practitioners and internists prescribe beta-blockers less frequently than cardiologists. This difference may be partly due to the fact that patients treated by non-specialists tend to be older and have more comorbidities. Another problem is the fear of side effects with beta-blockers. This is often due to lack of experience (particularly among primary care physicians), as in the past beta-blockers were considered contraindicated in CHF. Frequently cited reasons for not prescribing beta-blockers are advanced age, severe symptoms, and comorbidities (e.g. chronic lung disease, diabetes). In fact, most problems can be avoided if beta-blockers are started at a very low dose and titrated up step by step to the maximum tolerated dose. Mortality benefits are achieved even at doses much lower than the targets used in clinical trials. The CIBIS III results should now help to eliminate most of the doubts regarding the efficacy and tolerability of beta-blockade, even in the elderly patient population.Keywords
This publication has 21 references indexed in Scilit:
- Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite SequenceCirculation, 2005
- Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)European Heart Journal, 2005
- Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)European Heart Journal, 2005
- Comparison of Treatment Initiation with Bisoprolol Vs. Enalapril in Chronic Heart Failure Patients: Rationale and Design of CIBIS-IIIEuropean Journal of Heart Failure, 2004
- Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international surveyThe Lancet, 2002
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureNew England Journal of Medicine, 2001
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF)The Lancet, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991